Back to Search
FRANCIS WORDEN, MD
MD
Medical Oncology Physician
NPI: 1700962677IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
4301062144(MI)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
4301062144(MI)
Pediatrics Physician
Pediatrics
Code: 208000000X
4301062144(MI)
Education
INDIANA UNIVERSITY SCHOOL OF MEDICINE
Class of 1993
Research & Publications (20)
Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
PMID 19504552·Laryngoscope·2009
4-observational
Controversies in the management of oropharynx cancer.
PMID 18691459·J Natl Compr Canc Netw·2008
6-review
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.
PMID 18474879·J Clin Oncol·2008
8-other
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
PMID 16779801·Cancer·2006
3-trial
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
PMID 15625365·J Clin Oncol·2005
3-trial
Therapeutic advances in small cell lung cancer.
PMID 11060696·Expert Opin Investig Drugs·2000
6-review
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
PMID 19649631·Cancer Chemother Pharmacol·2010
3-trial
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
PMID 19225720·Invest New Drugs·2009
3-trial
Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy.
PMID 19189338·Head Neck·2009
3-trial
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
PMID 19057272·J Thorac Oncol·2008
3-trial
Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study.
PMID 19028268·Int J Radiat Oncol Biol Phys·2008
8-other
NCCN Task Force Report: mTOR inhibition in solid tumors.
PMID 18926092·J Natl Compr Canc Netw·2008
6-review
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
PMID 18541897·J Clin Oncol·2008
3-trial
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.
PMID 18474878·J Clin Oncol·2008
8-other
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.
PMID 17848274·Int J Radiat Oncol Biol Phys·2007
8-other
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
PMID 17848273·Int J Radiat Oncol Biol Phys·2007
8-other
Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
PMID 17560051·Int J Radiat Oncol Biol Phys·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 EAST MEDICAL CENTER DR, B1 FLOOR CANCER & GERIATRICS CTR RECP C
ANN ARBOR, MI 48109 - Phone
- (734) 647-8902
Quick Facts
- NPI
- 1700962677
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile